Acute adverse reactions to magnetic resonance contrast media-- XXXX chelates.

@entity1 @entity1353 @entity565 @entity26 @entity22226 @entity56 @entity2287
The objective of this study was to evaluate the clinical safety of intravenous @entity2287 -based contrast media used in @entity1 who underwent MRI at a single institution. Acute adverse reactions to intravenous @entity2287 -based contrast media used for MRI at the Princess Margaret Hospital, Hong Kong, @entity22226 , from January 1999 to November 2004 were recorded in an incidence log book. The medical records of @entity1 ' demographics were retrospectively reviewed and the nature, frequency and severity of the adverse reactions were investigated and documented. The incidence of acute adverse reactions to intravenous @entity2287 -based contrast media was 0.48% (45 @entity1 with 46 adverse reactions). The severity of these adverse reactions were 96% mild, 2% moderate (one @entity1 developed @entity1353 that required @entity26 supplementation and intravenous steroidal management) and 2% severe (one @entity1 developed an anaphylactoid reaction, but successfully recovered through timely resuscitation). No @entity1 were recorded as having contrast extravasation and none died as a result of any adverse reaction. Among the 45 @entity1 who developed adverse reactions, three @entity1 (6.7%) had prior adverse reactions to iodinated contrast media, three (6.7%) had prior reactions to a different @entity2287 -based contrast agent, one (2%) had @entity565 and nine (20%) had a history of @entity56 . Overall, 41% of the adverse reactions were not documented in the final MRI report or the clinical medical records. @entity2287 -based contrast media are safe and well tolerated by the vast majority of @entity1 . In our study, the adverse reaction rate (0.48%) and the incidence of severe anaphylactoid reaction (0.01%) concur with those reported in the literature. Although most of the symptoms are mild and transient, these adverse reactions must be accurately documented and managed.
